RxDoctor Payments DataLook up a doctor →

Asaff Harel

Neurology · New York, NYNPI 1487945465

Payments from drug & device makers

$853,615in general payments, 2019–2025

Across 307 payments — averaging $2780.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$444K
  • TG Therapeutics, Inc.$152K
  • AstraZeneca$86K
  • Amgen$52K
  • Roche Products Limited$40K
  • Biogen$33K
  • plus $47K from 8 others

What the payments were for

  • Consulting fees$24,77514%
  • Speaking & faculty fees$140,21578%
  • Travel & lodging$8,5125%
  • Food & beverage$5,6433%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$853,615 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$125,613
Medicare patients
126
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab77$660,213
OcrevusOcrelizumab17$637,343
SolirisEculizumab13$334,986
Teriflunomide76$306,343
VumerityDiroximel Fumarate35$293,885
TysabriNatalizumab32$269,466
EnspryngSatralizumab-Mwge11$228,560
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$220,606
Dimethyl Fumarate46$57,389
Glatiramer Acetate11$31,142
NucyntaTapentadol Hcl30$30,557
Dalfampridine ErDalfampridine74$25,744
UbrelvyUbrogepant14$16,837
Emgality PenGalcanezumab-Gnlm13$9,238
MyrbetriqMirabegron12$5,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Ocrevus$444,139$637,34317 claims
BiogenVumerity, Tysabri$32,922$563,35167 claims
AstraZenecaSoliris$85,962$334,98613 claims
Genentech USA, Inc.Enspryng$8,045$228,56011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →